© 2021 MJH Life Sciences™ and OncLive. All rights reserved. https://www.onclive.com/news OncLive articles OncLive articles en-us Sat, 28 Dec 2024 01:18:35 +0000 5 144 47 https://www.onclive.com/news https://www.onclive.com/logo32_onclive.png https://www.onclive.com/view/fda-approves-subcutaneous-nivolumab-in-advanced-or-metastatic-solid-tumors OncLive Articles us Fri, 27 Dec 2024 16:52:29 +0000 <![CDATA[The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.]]> OncLive https://www.onclive.com/rss/fda-approves-subcutaneous-nivolumab-in-advanced-or-metastatic-solid-tumors https://www.onclive.com/view/a-sense-of-culture-and-community-sparked-a-passion-in-genitourinary-oncology OncLive Articles us Fri, 27 Dec 2024 16:00:00 +0000 <![CDATA[A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, is also working to shape the next generation’s minds of medicine to improve outcomes further. ]]> OncLive https://www.onclive.com/rss/a-sense-of-culture-and-community-sparked-a-passion-in-genitourinary-oncology https://www.onclive.com/view/reflections-of-an-inaugural-gynecologic-oncology-fellow OncLive Articles us Fri, 27 Dec 2024 15:00:00 +0000 <![CDATA[]]> OncLive https://www.onclive.com/rss/reflections-of-an-inaugural-gynecologic-oncology-fellow https://www.onclive.com/view/a-pioneering-journey-in-radiation-oncology-inspired-by-multidisciplinary-collaboration OncLive Articles us Fri, 27 Dec 2024 14:00:00 +0000 <![CDATA[Fueled by wanting to carry on his father’s legacy, Ralph R. Weichselbaum, MD, created his own mark on radiation therapy in oncologic care.]]> OncLive https://www.onclive.com/rss/a-pioneering-journey-in-radiation-oncology-inspired-by-multidisciplinary-collaboration https://www.onclive.com/view/new-advances-in-waldenstr-m-macroglobulinemia OncLive Articles us Fri, 27 Dec 2024 13:00:00 +0000 <![CDATA[Understanding Waldenström Macroglobulinemia, and genomic profiles influencing clinical presentation and treatment strategies.]]> OncLive https://www.onclive.com/rss/new-advances-in-waldenstr-m-macroglobulinemia https://www.onclive.com/view/fda-approves-tislelizumab-plus-chemo-for-pd-l1-unresectable-or-metastatic-gastric-gej-cancer OncLive Articles us Fri, 27 Dec 2024 12:16:16 +0000 <![CDATA[The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.]]> OncLive https://www.onclive.com/rss/fda-approves-tislelizumab-plus-chemo-for-pd-l1-unresectable-or-metastatic-gastric-gej-cancer https://www.onclive.com/view/the-evolving-role-of-ctdna-in-guiding-adjuvant-chemotherapy-decisions-in-crc-insights-from-stacey-a-cohen-md OncLive Articles us Thu, 26 Dec 2024 19:00:00 +0000 <![CDATA[Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.]]> OncLive https://www.onclive.com/rss/the-evolving-role-of-ctdna-in-guiding-adjuvant-chemotherapy-decisions-in-crc-insights-from-stacey-a-cohen-md https://www.onclive.com/view/national-fellows-forum-highlights-future-research-directions-in-hgsoc-and-hcc OncLive Articles us Thu, 26 Dec 2024 15:00:00 +0000 <![CDATA[]]> OncLive https://www.onclive.com/rss/national-fellows-forum-highlights-future-research-directions-in-hgsoc-and-hcc https://www.onclive.com/view/uncovering-the-power-of-introspection-to-drive-personalized-cancer-care OncLive Articles us Thu, 26 Dec 2024 14:00:00 +0000 <![CDATA[A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified him on the patient journey and enhancing their quality of care.]]> OncLive https://www.onclive.com/rss/uncovering-the-power-of-introspection-to-drive-personalized-cancer-care https://www.onclive.com/view/allosteric-inhibitors-targeting-pik3ca-may-reduce-treatment-toxicities-in-breast-cancer OncLive Articles us Thu, 26 Dec 2024 13:00:00 +0000 <![CDATA[Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.]]> OncLive https://www.onclive.com/rss/allosteric-inhibitors-targeting-pik3ca-may-reduce-treatment-toxicities-in-breast-cancer https://www.onclive.com/view/exploring-luspatercept-s-role-in-anemia-management-for-lower-risk-mds-insights-from-dr-jorge-cortes- OncLive Articles us Wed, 25 Dec 2024 19:00:00 +0000 <![CDATA[Jorge Cortes, MD discusses the FDA approval of luspatercept-aamt has influenced first-line MDS management.]]> OncLive https://www.onclive.com/rss/exploring-luspatercept-s-role-in-anemia-management-for-lower-risk-mds-insights-from-dr-jorge-cortes- https://www.onclive.com/view/pilot-program-improves-palliative-care-training-for-hematology-oncology-fellows OncLive Articles us Wed, 25 Dec 2024 14:00:00 +0000 <![CDATA[The director of the Hematology/Oncology Fellowship Training Program at Fox Chase Cancer Center discusses palliative care training for hematology/oncology fellows and highlights a pilot study aimed at improving this area of training.]]> OncLive https://www.onclive.com/rss/pilot-program-improves-palliative-care-training-for-hematology-oncology-fellows https://www.onclive.com/view/summary-of-recent-advances-and-unmet-needs-for-patients-with-ebc OncLive Articles us Wed, 25 Dec 2024 13:05:00 +0000 <![CDATA[Panelists discuss key updates from the past year regarding HR+/HER2– early breast cancer (eBC), emerging research that could transform treatment approaches, and the role of new biomarkers in patient identification, stratification, and predicting CDK4/6 inhibitor responses; they also highlight studies on the horizon that may further refine treatment strategies and offer closing clinical pearls for diagnosing and managing early-stage breast cancer.]]> OncLive https://www.onclive.com/rss/summary-of-recent-advances-and-unmet-needs-for-patients-with-ebc https://www.onclive.com/view/initial-approach-to-management-of-ret-positive-nsclc OncLive Articles us Wed, 25 Dec 2024 13:05:00 +0000 <![CDATA[Panelists discuss the initial approach to the management of RET-positive non–small cell lung cancer (NSCLC), focusing on treatment strategies and the role of targeted therapies such as RET inhibitors in first-line treatment.]]> OncLive https://www.onclive.com/rss/initial-approach-to-management-of-ret-positive-nsclc https://www.onclive.com/view/practice-takeaways-treating-mf-patients-key-strategies-for-community-providers OncLive Articles us Wed, 25 Dec 2024 13:00:00 +0000 <![CDATA[Panelists share their closing thoughts and practice pearls, offering key insights and takeaways for community oncologists based on discussing treatment strategies in myelofibrosis.]]> OncLive https://www.onclive.com/rss/practice-takeaways-treating-mf-patients-key-strategies-for-community-providers https://www.onclive.com/view/optimizing-parp-inhibitor-duration OncLive Articles us Wed, 25 Dec 2024 13:00:00 +0000 <![CDATA[Panelists discuss how the duration of PARP inhibitor (PARPi) therapy typically differs between the first-line and second-line settings in advanced ovarian cancer treatment.]]> OncLive https://www.onclive.com/rss/optimizing-parp-inhibitor-duration https://www.onclive.com/view/novel-therapies-and-combinations-augment-melanoma-treatment-arsenal OncLive Articles us Wed, 25 Dec 2024 13:00:00 +0000 <![CDATA[Omid Hamid, MD, discusses recent advances in the melanoma treatment landscape and highlights the 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.]]> OncLive https://www.onclive.com/rss/novel-therapies-and-combinations-augment-melanoma-treatment-arsenal https://www.onclive.com/view/multidisciplinary-treatment-sequencing-and-coordination OncLive Articles us Wed, 25 Dec 2024 13:00:00 +0000 <![CDATA[Panelists discuss their approach to sequencing surgery, radiation, and systemic therapies for early-stage breast cancer patients, emphasizing the guiding principles of treatment sequencing and how individual patient factors influence decisions; they also highlight the importance of multidisciplinary coordination, identifying key specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the critical role of including the patient in these discussions.]]> OncLive https://www.onclive.com/rss/multidisciplinary-treatment-sequencing-and-coordination https://www.onclive.com/view/clinical-decision-making-when-to-treat-advanced-nsclc-without-mutational-results OncLive Articles us Wed, 25 Dec 2024 13:00:00 +0000 <![CDATA[Panelists discuss how to balance the need for comprehensive biomarker testing with the urgency to initiate treatment in patients with advanced disease and explore situations where treatment might be started before test results are available.]]> OncLive https://www.onclive.com/rss/clinical-decision-making-when-to-treat-advanced-nsclc-without-mutational-results https://www.onclive.com/view/sarting-with-a-patient-case-45ym-high-risk-t4n0-resected-crc---what-are-next-steps- OncLive Articles us Tue, 24 Dec 2024 18:18:47 +0000 <![CDATA[Panelists review a patient case of a 45 year old man with high-risk T4N0 resected CRC.]]> OncLive https://www.onclive.com/rss/sarting-with-a-patient-case-45ym-high-risk-t4n0-resected-crc---what-are-next-steps- https://www.onclive.com/view/asciminib-and-ponatinib-sit-at-the-forefront-of-advances-in-cml-management-insights-from-onyee-chan-md-and-bradley-d-hunter-md OncLive Articles us Tue, 24 Dec 2024 18:00:00 +0000 <![CDATA[Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.]]> OncLive https://www.onclive.com/rss/asciminib-and-ponatinib-sit-at-the-forefront-of-advances-in-cml-management-insights-from-onyee-chan-md-and-bradley-d-hunter-md https://www.onclive.com/view/car-t-cell-therapy-for-b-all OncLive Articles us Tue, 24 Dec 2024 17:58:22 +0000 <![CDATA[A panelist discusses how CAR-T cell therapy patient selection involves evaluating disease characteristics like relapse/refractory status and tumor burden, patient-specific factors including performance status and organ function, with extramedullary disease requiring careful monitoring while isolated CNS disease may warrant alternative treatments or clinical trials.]]> OncLive https://www.onclive.com/rss/car-t-cell-therapy-for-b-all https://www.onclive.com/view/glofitamab-plus-gemcitabine-and-oxaliplatin-glofit-gemox-for-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-results-of-a-global-randomized-phase-iii-trial-starglo- OncLive Articles us Tue, 24 Dec 2024 17:18:11 +0000 <![CDATA[Dr. Haifaa Abdulhaq presents results from the global Phase III STARGLO trial, demonstrating the superior overall survival, progression-free survival, and complete response rates of glofitamab combined with gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab-based therapy (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma, with a tolerable safety profile.]]> OncLive https://www.onclive.com/rss/glofitamab-plus-gemcitabine-and-oxaliplatin-glofit-gemox-for-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-results-of-a-global-randomized-phase-iii-trial-starglo- https://www.onclive.com/view/daiichi-sankyo-astrazeneca-withdraw-eu-maa-for-dato-dxd-in-advanced-nonsquamous-nsclc OncLive Articles us Tue, 24 Dec 2024 15:39:27 +0000 <![CDATA[European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.]]> OncLive https://www.onclive.com/rss/daiichi-sankyo-astrazeneca-withdraw-eu-maa-for-dato-dxd-in-advanced-nonsquamous-nsclc https://www.onclive.com/view/key-considerations-when-ordering-biomarker-testing OncLive Articles us Tue, 24 Dec 2024 14:57:32 +0000 <![CDATA[Panelists discuss how oncologists prioritize factors like turnaround speed, test comprehensiveness, proven clinical utility, and individual patient characteristics when ordering biomarker testing to guide cancer treatment decisions.]]> OncLive https://www.onclive.com/rss/key-considerations-when-ordering-biomarker-testing https://www.onclive.com/view/clinical-scenario-1-a-her2-mbc-patient-with-trastuzumab-deruxtecan-with-brain-mets OncLive Articles us Tue, 24 Dec 2024 14:48:12 +0000 <![CDATA[Panelists discuss how trastuzumab deruxtecan (Enhertu) is used to treat HER2-positive metastatic breast cancer with brain metastases, emphasizing its effectiveness in achieving systemic tumor reduction and CNS lesion stabilization while exploring treatment challenges and emerging strategies in this patient population.]]> OncLive https://www.onclive.com/rss/clinical-scenario-1-a-her2-mbc-patient-with-trastuzumab-deruxtecan-with-brain-mets https://www.onclive.com/view/diagnosis-and-risk-stratification-for-early-stage-hr-her2--breast-cancer OncLive Articles us Tue, 24 Dec 2024 14:44:37 +0000 <![CDATA[Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2- early-stage breast cancer inform clinical decision-making, with an emphasis on biomarker testing, the use of tools like RSClin N+, and the evolving role of CDK4/6 inhibitors and adjuvant therapies. They also address challenges in risk assessment and the integration of newer treatment strategies, such as CDK4/6 inhibitors and PARP inhibitors in the early-stage setting. ]]> OncLive https://www.onclive.com/rss/diagnosis-and-risk-stratification-for-early-stage-hr-her2--breast-cancer https://www.onclive.com/view/defining-resectability-in-stage-iii-nsclc-addressing-key-controversies OncLive Articles us Tue, 24 Dec 2024 14:31:50 +0000 <![CDATA[Panelists discuss how the resectability of stage III non-small cell lung cancer tumors remains controversial, particularly regarding the role of surgery in multi-station N2 disease and the optimal sequencing of multimodality therapy.]]> OncLive https://www.onclive.com/rss/defining-resectability-in-stage-iii-nsclc-addressing-key-controversies https://www.onclive.com/view/expert-insights-in-selecting-frontline-therapies-in-tn-cll-fixed-duration-venetoclax-vs-continuous-btki OncLive Articles us Tue, 24 Dec 2024 14:30:00 +0000 <![CDATA[Matthew S. Davids, MD, MMSc; Alvaro Alencar, MD; Marc S. Hoffmann, MD; Brad S. Kahl, MD; and Nicole Lamanna, MD, engage in a comprehensive discussion of frontline CLL treatment strategies, examining factors influencing the choice between fixed-duration venetoclax-based therapy and continuous BTK inhibitors, analyzing long-term SEQUOIA trial data, evaluating real-world outcomes and adverse events with covalent BTK inhibitors, and assessing emerging combination approaches including zanubrutinib plus venetoclax.]]> OncLive https://www.onclive.com/rss/expert-insights-in-selecting-frontline-therapies-in-tn-cll-fixed-duration-venetoclax-vs-continuous-btki https://www.onclive.com/view/rewriting-the-rules-for-a-better-future-of-cancer-care OncLive Articles us Tue, 24 Dec 2024 14:00:57 +0000 <![CDATA[Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in diversifying clinical trials and improving quality of life.]]> OncLive https://www.onclive.com/rss/rewriting-the-rules-for-a-better-future-of-cancer-care